Benitec Biopharma Inc. (BNTC) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Benitec Biopharma Inc.

BNTC

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

205M

Biotechnology

Next Earning date - 11 Nov 2024

205M

Biotechnology

Next Earning date - 11 Nov 2024

11.48USD

0.26 ( 2.32%)

Relative Strenght

97

Volume Buzz

120%

Earning Acce

Yes

Dist 52w H.

11%

Quote Panel

Updated October 21, 2024

1W 17.02 % 1M 29.28 % 3M 28.12 % 1Y 256.52 %

Key Metrics

Market Cap
205.42M
Shares Outstanding
17.89M
Share in Float
14.93M
Dividende
0

Earning Date
11 Nov 2024
Price Target
11.48
Average Volume
27159
Beta
0.9

Range
2.69-12.89
Industry
Biotechnology
Website
https://benitec.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

34236.80x

P/S Ratio

0.99x

P/B Ratio

0.0

Debt/Equity

-362516.7%

Net Margin

$-5.5

EPS

How BNTC compares to sector?

P/E Ratio

Relative Strength

BNTC

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$1M

NaN%

2025-Revenue

$8.05

-594%

2025-EPS

$1M

79%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Oppenheimer

initialise

Previous: Not converted

2024-10-15

Now: Outperform

Guggenheim

initialise

Previous: Not converted

2024-09-12

Now: Buy

Piper Sandler

initialise

Previous: Not converted

2024-06-13

Now: Overweight

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-7.99
vs -10.54

Q4.22

N/A

-3.40
vs -10.03

Q1.23

N/A

-2.72
vs -6.80

Q2.23

N/A

-2.83
vs -10.54

Q3.23

N/A

-2.76
vs -7.99

Q4.23

N/A

-2.64
vs -3.40

Q1.24

N/A

-1.64
vs -2.72

Q2.24

N/A

-1.32
vs -2.83

Q3.24

N/A

-0.79
vs -2.76

Q4.24

N/A

-0.65
vs -2.64

Sales Growth

YoY

Current

Estimates

Q1.22

+4700%

48K vs 1K

Q2.22

-100%

NA vs 2K

Q3.22

NA

472K vs NA

Q4.22

-44%

14K vs 25K

Q1.23

+13%

54K vs 48K

Q2.23

NA

7K vs NA

Q3.23

-100%

NA vs 472K

Q4.23

-100%

NA vs 14K

Q1.24

-89%

6K vs 54K

Q2.24

-100%

NA vs 7K

Return on Equity

QoQ

Q3.22

-38%

-0.38
vs -1.76

Q4.22

-58%

-0.58
vs -0.38

Q1.23

-95%

-0.95
vs -0.58

Q2.23

-2307%

-23.07
vs -0.95

Q3.23

-27%

-0.27
vs -23.07

Q4.23

-44%

-0.44
vs -0.27

Q1.24

-37%

-0.37
vs -0.44

Q2.24

-10%

-0.10
vs -0.37

Institutionnal Ownership

QoQ

Q1.22

15

15
vs 13

15%

Q2.22

19

19
vs 15

27%

Q3.22

20

20
vs 19

5%

Q4.22

23

23
vs 20

15%

Q1.23

20

20
vs 23

-13%

Q2.23

16

16
vs 20

-20%

Q3.23

1

1
vs 16

-94%

Q2.24

1

1
vs NA

NA

Earnings Growth

Latest News

BNTC

globenewswire.com

6 hours ago

Benitec Biopharma Announces Updated Investor Webcast Information

BNTC

globenewswire.com

6 hours ago

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

BNTC

globenewswire.com

6 hours ago

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study

BNTC

globenewswire.com

8 hours ago

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

BNTC

seekingalpha.com

15 hours ago

Benitec Biopharma: OPMD Program Continues To Advance With Catalysts

BNTC

globenewswire.com

16 hours ago

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

New Feature Coming Soon, Stay Tuned!

Shape

Shape